What they found: Significant improvement in muscle insulin signaling (AKT/mTOR pathway) Increased expression of genes for mitochondrial biogenesis Increased expression of tissue remodeling Drop in HOMA-IR of ~25 % No adverse events Why it matters: This was the first high-quality randomized clinical trial of NMN in humans
DISSECTION O - ESOC25-604 FIBROMUSCULAR DYSPLASIA AND SPONTANEOUS CERVICAL ARTERY DISSECTION: A SECONDARY ANALYSIS OF THE STOP-CAD STUDY Ahmad Nehme 1 , Liqi Shu 2 , Marion Boulanger 1 , Daniel Mandel 2 , Christopher Leon Guerrero 3 , Esther Kim 3 , Nils Henninger 4 , Bastien Rioux 5 , Aaron Rothstein 6 , Michele Romoli 7 , Setareh Salehi Omran 8 , Marialuisa Zedde 9 , Richa Sharma 10 , Shadi Yaghi 2 , Emmanuel Touz 1 1 Department of Neurology, CHU de Caen-Normandie, Caen, France, 2 Department of Neurology, The Warren Alpert Medical School of Brown University, Brown Medical School, Providence, United States, 3 Sanger Heart and Vascular Institute, Atrium Health, Charlotte, United States, 4 Department of Neurology, University of Massachusetts Chan Medical School, Worcester, United States, 5 Department of Neurosciences, Universit de Montral, Montreal, Canada, 6 Department of Neurology, University of Pennsylvania, Philadelphia, United States, 7 Department of Neurosciences, Bufalini Hospital, Cesena, Italy, 8 Department of Neurology, University of Colorado, Aurora, United States, 9 Neurology Unit, Stroke Unit, Azienda Unit Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, 10 Department of Neurology, Yale New Haven Hospital, New Haven, United States Background and Aims: Fibromuscular dysplasia (FMD) is found in 6-14% of patients with spontaneous cervical artery dissection (sCeAD)
It is extracted during digestion and absorbed directly into the bloodstream
Nippon Genetics Europe) markers
Use of this information is at your own risk, and we are not liable for any outcomes resulting from its use.
